Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).
| Brand name | LISDEXAMFETAMINE DIMESYLATE |
| Generic name | LISDEXAMFETAMINE DIMESYLATE |
| Active ingredient(s) | LISDEXAMFETAMINE DIMESYLATE |
| Distributed by / for | Sun Pharmaceuticals, Inc., Cranbury, NJ 08512 |
| NDC | 57664-051-88 |
| Full product label | Lisdexamfetamine Dimesylate Capsules, 60 mg, CII, 100-count bottles, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceuticals, Inc., Cranbury, NJ 08512, NDC 57664-051-88 |
| Recalling firm | SUN PHARMACEUTICAL INDUSTRIES INC |
| Distribution | Recalled units were distributed to 17 distributors who may have further distributed the product nationwide. |
| Quantity | 5,448 bottles |
| Recall initiated | 2025-06-16 |
| Report date | 2025-07-23 |
| Recall completed | — |
| Recall number | D-0516-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Princeton NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗